Immunomodulators in the treatment of cutaneous lymphoma.
BACKGROUND
Cutaneous lymphoma involves clonal proliferation of immunocompetent cells. Immunointerventional strategies are a rational approach to the treatment of cutaneous lymphoma given the pathophysiological aspects of the disease.


OBJECTIVE
Immunomodulatory therapies in cutaneous lymphoma are reviewed, including interferons, interleukin-2, cyclosporin A, monoclonal antibodies, autologous bone marrow transplantation, fusion toxins, thymopentin and extracorporeal photopheresis as well as recently reported methods such as vaccination therapy, mycophenolate, and new retinoids.


CONCLUSIONS
Cutaneous lymphoma is sensitive to immunointerventions. This approach should be used in early stages of the disease when it is more susceptible and benefits better from immunomodulatory treatment modalities.
Rogalski
C
C
Clinic of Dermatology, University Hospital of Zürich, Switzerland.
Dummer
R
R
Burg
G
G
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D016025:Bone Transplantation; D006801:Humans; D007167:Immunotherapy; D007372:Interferons / Q000627:therapeutic use; D007376:Interleukin-2 / Q000627:therapeutic use; D008223:Lymphoma / Q000503:physiopathology / Q000628:therapy*; D012878:Skin Neoplasms / Q000503:physiopathology / Q000628:therapy*; D014182:Transplantation, Autologous
D000911:Antibodies, Monoclonal; D007376:Interleukin-2; D007372:Interferons